Please assess the completion status of the following clinical trial:

Trial Title: Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder, or schizoaffective disorder) or 298.9 (psychosis NOS)~2. Onset of psychosis no longer than 7 years ago~3. Minimum total PANSS score of 60~4. Age 18 -70 years~5. Patients are treated with antipsychotic medication~6. Written informed consent is obtained~7. Female patients of childbearing potential need to utilize a proper method of contraception (the pill, vaginal ring, hormonal patch, intrauterine device, cervical cap, condom, contraceptive injection, diaphragm) in case of sexual intercourse during the study.~Exclusion Criteria:~1. Presence of any of the contra-indications of prednisolone as reported in the SPC.~2. Presence of diabetes mellitus or random (non-fasting) glucose levels exceeding 11 mmol/L at screening, severe heart failure, severe osteoporosis or systemic fungal infections.~3. Body Mass Index (BMI) of \>30.0~4. Current or chronic use of systemic glucocorticosteroids (temporary use is permitted, if stopped 1 month before start of treatment trial)~5. Chronic use of non-steroidal anti-inflammatory drugs, defined as daily use during more than 2 months. Intermittent use is permitted, if stopped at least 1 month before start of treatment trial.~6. Pregnancy or breast-feeding. A urine pregnancy test will be performed at screening.~7. Concurrent use of certain types of medication:~1. liver enzyme inducing medication such as carbamazepine, riphampicine, primidone, barbiturates and phenytoine~2. HAART medication (both HIV protease inhibitors and (non)-nucleoside reverse transcriptase inhibitors), especially efavirenz, ritonavir and lopinavir.~3. telaprevir and boceprevir in treatment of Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prednisolone (Type: EXPERIMENTAL): Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).